Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prescription drug that’s used to treat prostate cancer in certain situations. Pluvicto comes as a solution for injection or infusion. Pluvicto is ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any ...

Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert. Patients with metastatic castration-resistant ...

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto to include hormone-sensitive prostate cancer (HSPC). The new results come from the ...